Navigation Links
Enobia Pharma Raises $40.1 Million Series B Financing
Date:9/11/2007

MONTREAL and QUEBEC, Sept. 11 /PRNewswire/ -- Enobia Pharma Inc, announced today that it raised $Cdn 40.1 Million in a Series B multi-tranche financing. The proceeds will be used primarily to fund the Company's novel hypophosphatasia drug development program through Phase 2 clinical trials. There is no known cure for hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone.

The financing was co-led by new investors OrbiMed Advisors LLC ("OrbiMed") of New York and CTI Life Sciences Fund of Montreal ("CTI"). The Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000, current investors in the Company, also participated in the round.

Robert Heft, PhD, President and CEO of Enobia said, "With no drug therapy available, hypophosphatasia patients and their families experience prolonged and significant suffering. We are pleased that we were able to attract such world class investors to our company at this important time in our development. We are confident that with their support, we will build on our promising preclinical results to advance the clinical development program of an enzyme replacement therapy for hypophosphatasia."

Jonathan Silverstein, General Partner of OrbiMed said, "We are delighted to be associated with this impressive team working on such a debilitating disease for which there is no cure."

Richard Meadows, Managing Partner of CTI said, "This represents an example of the type of high quality investment opportunity that exists in Quebec and that is capable of attracting the attention and significant investment from our U.S. VC colleagues."

Both Mr. Silverstein and Mr. Meadows will join the newly constituted Board, which also includes: Robert Heft, who previously served on the Board; Fredric Price, also a former Board member, and an investor in this Series B financing who was previously Chairman & CEO of BioMarin Pharmaceutical and Thomas Schuetz, MD, PhD, wh
'/>"/>

SOURCE Enobia Pharma Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... New Brunswick, NJ (PRWEB) November 18, 2014 ... of Data Quality and Transparency Reporting solutions, announced ... has gone live using its Consummate Providerâ„¢ solution ... Consummate Providerâ„¢ is a Global, SaaS based, Data ... Science organizations and their third party Providers improve ...
(Date:11/18/2014)... Ft. Lauderdale, FL (PRWEB) November 18, 2014 ... 12) have announced the launch of PAWSitively Curing ... Awareness Month. This new 501(c) (3) non-profit organization is ... Every dollar donated goes directly to the University ... proud to partner with PAWSitively Curing Cancer as the ...
(Date:11/18/2014)... Philadelphia, PA (PRWEB) November 18, 2014 ... healthcare planning and design expertise to the nation's hospitals ... is best served by those dedicating their careers to ... As a respected contributor in her respective field, Laura ... engineering expertise at the 2014 Winter Simulation Conference. ...
(Date:11/18/2014)... , Nov. 18, 2014  Asterias Biotherapeutics, ... in the emerging field of regenerative medicine, today ... (oligodendrocyte progenitor cells) for complete cervical spinal cord ... ten "Top Advanced Therapies Projects to Watch" by ... to receive this significant industry honor, which represents ...
Breaking Biology Technology:Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 3
... NEW YORK, Jan. 27, 2011 The Alzheimer,s ... has awarded a grant of $195,000 to ALS ... toxic proteins implicated in Alzheimer,s disease. ... will identify and develop small-molecule brain-penetrant inducers of ...
... SAN CARLOS, Calif. and HOPKINTON, Mass., Jan. 27, ... Sciences, Inc. (Nasdaq: CALP ) today ... automated methods for next generation sequencing sample preparation ... to enable researchers to leverage NuGEN,s Ovation® and ...
... technique for rapidly prototyping nanoscale devices and structures that ... away when done. Hard-tip, soft-spring lithography (HSL) rolls ... high resolution -- and the best of polymer pen ... HSL could be used in the areas of electronics ...
Cached Biology Technology:Alzheimer's Drug Discovery Foundation Funds ALS Biopharma to Develop Small Molecules for Alzheimer's Disease 2NuGEN and Caliper Partner to Eliminate Next-Gen Sequencing Sample Preparation Bottlenecks 2NuGEN and Caliper Partner to Eliminate Next-Gen Sequencing Sample Preparation Bottlenecks 3Making a point 2Making a point 3
(Date:11/4/2014)... 4, 2014   Neurotechnology , a provider ... the latest version of its fingerprint matching algorithm ... MINEX evaluation organized by NIST. The MINEX ... the INCITS 378 fingerprint standard template format. MINEX ... tenders in the United States ...
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
(Date:11/2/2014)... support of a bold quest to rid the world ... today announced an award of US$156 million to PATH ... building new vaccines that will interrupt the cycle of ... zero" agenda. Such vaccines would ensure that parasite reintroduction ... "immunological bed net." , This approach to developing ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... provide a look at the ash and gas clouds being ... NOAA,s GOES-13 satellite to provide a week long look at ... westerly winds carry the debris (ash and smoke) far to ... down the ash before it can go far in the ...
... 2012 Scientists at The Scripps Research Institute have ... the market to treat neuropathic pain and epilepsy, helps ... treatments, gabapentin targets stress systems in the brain that ... 12-week trial of 50 treatment-seeking cannabis users, those who ...
... /PRNewswire-iReach/  -- Global Information Inc. is announces limited time ... important Boston healthcare conferences: Next-Gen Kinase ... rapidly maturing kinase inhibitors field will gather to explore ... Next-Gen Kinase Inhibitors Conference in Cambridge, MA. ...
Cached Biology News:NASA's new satellite movie of 1 week's ash activity from Mexico's Popocatepetl Volcano 2Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit 2Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit 3Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3